# A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

> **NCT03596762** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 199 (actual)

## Conditions studied

- Menopause
- Hot Flashes
- Night Waking

## Interventions

- **DRUG:** Elinzanetant (BAY3427080)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03596762
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-20
- **Primary completion:** 2019-11-21
- **Final completion:** 2019-11-21
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2023-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03596762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03596762, "A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03596762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*